Literature DB >> 228431

Operative approach to pancreatic carcinoma.

J R Brooks.   

Abstract

It is apparent that we are dealing with a very lethal disease. It is also apparent that this disease is increasing in frequency. In terms of treatment, it is clear that the survival figures between carcinoma of the pancreas and carcinoma of the common duct, papilla of Vater, or duodenum present great differences. The pancreatic tumors do very poorly by comparison. A comparison of the survival figures following a Whipple resection and following a bypass procedure reveal similar results, except when dealing with a very small pancreatic head lesion or when dealing with a malignancy of the papilla of Vater, lower end of common duct, or duodenum. The latter tumor types do better with a Whipple resection than a bypass. A comparison between total pancreatectomy and a Whipple resection for ductal carcinoma of the pancreatic head reveals better results in terms of length of survival following total pancreatectomy as long as one considers only Stage I or Stage II disease and excludes Stage III disease. A Whipple procedure is advocated for carcinoma of the papilla of Vater, common duct, or duodenum, because survival figures are quite good and many patients escape the need for insulin and pancreatic extract replacement. It is too early to evaluate the survival figures that follow regional pancreatectomy.

Entities:  

Mesh:

Year:  1979        PMID: 228431

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  5 in total

Review 1.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

2.  Cancer of the pancreas: palliative operation, Whipple procedure, or total pancreatectomy.

Authors:  W P Longmire
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

3.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

Authors:  W K Ward; D C Bolgiano; B McKnight; J B Halter; D Porte
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

4.  Adaptation of ovine fetal pancreatic insulin secretion to chronic hypoglycaemia and euglycaemic correction.

Authors:  Sean W Limesand; William W Hay
Journal:  J Physiol       Date:  2002-10-04       Impact factor: 5.182

5.  Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer.

Authors:  D L Trump; J A Hathorn; L B Grochow; D Spriggs; M L Eble; J A Hohneker
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.